MannKind (MNKD) Set to Post Quarterly Earnings on Wednesday

MannKind (NASDAQ:MNKD) is projected to post its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to announce earnings of ($0.0575) per share and revenue of $107.74 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 9:00 AM ET.

MannKind (NASDAQ:MNKD) last released its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($0.01) EPS for the quarter, hitting analysts’ consensus estimates of ($0.01). The business had revenue of $109.37 million for the quarter, compared to the consensus estimate of $108.08 million. During the same period in the previous year, the business posted $0.05 earnings per share. MannKind’s revenue was up 43.0% on a year-over-year basis. On average, analysts expect MannKind to post ($0.21) EPS for the current fiscal year and $0.01 EPS for the next fiscal year.

MannKind Trading Up 1.9%

Shares of MannKind stock opened at $3.29 on Wednesday. The firm’s 50-day simple moving average is $3.63 and its 200-day simple moving average is $3.79. MannKind has a twelve month low of $2.23 and a twelve month high of $6.51.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Zacks Research upgraded MannKind from a “strong sell” rating to a “hold” rating in a research note on Monday, October 5th. Cantor Fitzgerald restated an “overweight” rating and set a $8.00 target price on shares of MannKind in a research report on Tuesday, October 20th. Wall Street Zen lowered MannKind from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Weiss Ratings reiterated a “sell (d)” rating on shares of MannKind in a research report on Friday, October 2nd. Finally, Chardan Capital began coverage on MannKind in a research note on Monday, October 19th. They set a “buy” rating and a $10.00 price objective for the company. Eight investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $8.08.

Insiders Place Their Bets

In other news, Director Steven Binder sold 39,051 shares of MannKind stock in a transaction that occurred on Friday, September 25th. The shares were sold at an average price of $3.29, for a total value of $128,477.79. Following the completion of the transaction, the director owned 713,258 shares in the company, valued at approximately $2,346,618.82. The trade was a 5.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold 111,660 shares of company stock worth $414,881 over the last quarter. 2.60% of the stock is currently owned by corporate insiders.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).